5 Oct 2020 12:07
5 October 2020
e-therapeutics plc
("e-therapeutics" or the "Company")
Notice of Interim Results
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), will announce its interim results for the half-year ended 31 July 2020 on Monday, 12 October 2020.
For further information, please contact:
e-therapeutics plc Ali Mortazavi, Executive Chairman Laura Roca-Alonso, Chief Business Officer
| Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
FTI Consulting Simon Conway/Stephanie Cuthbert | Tel: +44 (0) 203 727 1000 Email: e-therapeutics@fticonsulting.com |
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.